# Daily Iteration Report — 2026-06-10 (Wednesday)

## Summary
Worked 4 queue items + mandatory sweeps. State loaded and saved (`agent_state.json`). All 285 papers remain vetted (272 VETTED / 13 FLAGGED; 0 unvetted). Not Monday → weekly new-paper sweep skipped.

## Step 4 — Credibility sweep (every run): CLEAN
- No fabricated PMIDs (>42,000,000) in any script.
- No "zero SAEs" / "zero rejection" claims.
- "achieves" hits are all benign: TTP399 tissue-selectivity (mechanistic design), LADA cost-effectiveness model, microbiome ML macro-AUC metric, and the verifier's own flag-word list. No overstated preclinical efficacy.

## Path validation (5 paths)
| Path | Rating | Basis |
|---|---|---|
| dapagliflozin → cardiovascular | **VALIDATED** | DAPA-HF+DELIVER pooled patient-level MA (n=11,007): CV death HR 0.86 (0.76–0.97), total HF hosp RR 0.71 (0.65–0.78), MACE HR 0.90. PMIDs 36041242, 38573262 |
| belatacept → islet_transplant | **VALIDATED** (small-n) | NHP belatacept+sirolimus prolongs islet allograft survival (225 vs 8 d); human calcineurin-sparing series 70% insulin-independent at 10y. PMIDs 23347226, 37359825. Rejection not fully eliminated. |
| NLRP3_inflammasome → T2D | **VALIDATED** | IAPP oligomers activate NLRP3 → IL-1β (Nat Immunol, PMID 20835230); macrophage NLRP3-ASC → β-cell loss (PMID 23955712). One db/db contradicting report noted. |
| rapamycin → islet_transplant | **VALIDATED** | Sirolimus = Edmonton-protocol maintenance cornerstone, most-used IS in clinical islet transplant (PMID 18713146). |
| vitamin_d → autoimmune | **PARTIALLY_VALIDATED** | Observational Finnish-cohort signal (2000 IU/d) + small RCT Treg/GAD65 effects, BUT 2025 systematic review/MA found no effect on T1D incidence (OR 0.55, 0.22–1.38) or islet autoimmunity (OR 0.91, 0.67–1.25). PMID 40988828. |

`validated_paths`: 35 rated entries (was 30).

## search_pubmed — Abata ABA-201
TCR-engineered autologous Treg therapy for T1D with residual β-cell function; first clinical study reportedly initiated 2024. **No first-in-human peer-reviewed safety/efficacy readout** as of today. No new PMID. Recheck 2026-07-02.

## audit_gap — Gap #14 (BRONZE: Personalized Nutrition for LADA)
PubMed/web search for LADA-specific personalized-nutrition RCTs or systematic reviews (2025–2026): **none found**. Only a single case report (PMC10553975) and consensus statements explicitly calling for large LADA RCTs (Diabetes 2020;69(10):2037). **Retain BRONZE; not a SILVER promotion candidate.** Next audit ~2026-07-10.

## Step 5 — Pipeline rebuild
`run_quality_improvements.py` → **all 41 improvements [OK]**.

## Step 6 — Commit/push: STILL BLOCKED (user action required)
- `.git/index.lock` cannot be removed in sandbox (OneDrive: Operation not permitted).
- `git push` fails: no GitHub auth in sandbox ("could not read Username").
- Branch is **ahead of origin/main by 37 commits**; today's changes are saved to working files but uncommitted.
- **USER ACTION** (PowerShell at `C:\Users\justi\OneDrive\Diabetes_Research`):
  ```
  Remove-Item .git\index.lock -ErrorAction SilentlyContinue
  Remove-Item .git\HEAD.lock  -ErrorAction SilentlyContinue
  git add -A
  git commit -m "Daily iterations through 2026-06-10"
  git push origin main
  ```

## Files changed
- `Analysis/Results/agent_state.json` (5 path validations, Abata topic check, Gap #14 audit, run history, reprioritized queue)
- Pipeline-regenerated dashboards/citations (41 builders)
- This report
